Here, we identified similar prevalence rates of PD-L1 tumor cell expression as previously reported.40 Of interest, we discovered that when using both CGP and PD-L1 IHC, these CDx biomarkers identified independent subsets of patients that are potentially eligible for pembrolizumab, with some overlap suggesting that it is important to test with both PD-L1 IHC and CGP to identify the NSCLC-BM patients that are eligible for pembrolizumab. Here, CD274 is linked to neoplasm.